This information
collection is approved through 7-96 under the following conditions:
upon resubmission of this collection HCFA will report on the
implementation status of this new form; reaction by drug
manufacturers, and the overall success in reducing the number of
disputes between manufacturers and the States. HCFA will
incorporate comments from the NPRM. HCFA will place the OMB number
on the first page of the form, along with an estimate of the burden
on respondents. In addition, HCFA will add a statement in the
instructions notifying manufacturers that if they do not have a
dispute with the invoice, they do not have to complete the RAR and
may send payment with the invoice alone.
Inventory as of this Action
Requested
Previously Approved
07/31/1996
07/31/1996
1,928
0
0
116,896
0
0
0
0
0
OBRA 1990 REQUIRES DRUG MANUFACTURERS
TO ENTER INTO AND HAVE IN EFFECT A REBATE AGREEMENT WITH HCFA FOR
STATES TO RECEIVE FUNDING FOR DRUGS DISPENSED TO MEDICAID
RECIPIENTS. 42 CFR 447.534 AND 447.536 REQUIRE MANUFACTURERS TO
REPORT SPECIFIC DRUG REBATE INFORMATION TO STATES WHEN PAYMENT IS
MADE.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.